Effect of Erythropoietin Stimulating Agents on Cardiovascular Events in Chronic Kidney Disease Patients on Hemodialysis

  • Ali Asad Khan King Edward Medical University
  • Somia Iqtadar
  • Yasir Shafi
  • Sajid Abaidullah
  • Aasma Refai

Abstract

Objectives:  Patients with chronic kidney disease (CKD) develop anemia which is treated with erythropoietin-stimulating agents (ESAs). However, ESAs do not reduce the risk of cardiovascular mortality. Furthermore, this is unclear whether ESAs therapy has any association with adverse cardiovascular events.Methods:  After an informed consent 275 male and female patients, between ages 35 to 75 years, with CKD stage V on ESAs undergoing twice weekly hemodialysis were enrolled. The dose of ESAs was calculated according to weight as 50mg/kg with target hemoglobin being 11 – 12 g/dl. Dose adjustments were made in the patients who failed to achieve target hemoglobin. The patients were followed for a year with the primary end point being new evidence of acute myocardial infarction (MI) diagnosed through ECG or echocardiography. Safety outcomes included stroke or death.Results:  The data was entered and analyzed in Statistical Package for Social Sciences (SPSS) version 18Out of 275 patients, 164 (59.6%) patients were males and 111 (40.4%) were females. Mean age of the patients was 51.52 with standard deviation of ± 5.73. According to the results, 52 (18.9%) patients reported with MI and 223 (81.1%) patients had no evidence of MI. Out of 52 patients who had MI, 37 (71.1%) were males and 15 (28.8%) patients were female.Conclusion:  ESAs are associated with an increased risk of MI in CKD patients on hemodialysis. Whether there is a direct association or there are other factors involved remains to be seen.
Published
2017-06-10
How to Cite
KHAN, Ali Asad et al. Effect of Erythropoietin Stimulating Agents on Cardiovascular Events in Chronic Kidney Disease Patients on Hemodialysis. Annals of King Edward Medical University, [S.l.], v. 23, n. 2, june 2017. ISSN 2079-0694. Available at: <http://www.annalskemu.org/journal/index.php/annals/article/view/1577>. Date accessed: 21 aug. 2017. doi: https://doi.org/10.21649/akemu.v23i2.1577.
Section
Articles

Keywords

Chronic Kidney Disease, Erythropoietin stimulating agents, Myocardial Infarction, Anemia

Most read articles by the same author(s)

1 2 > >>